Comparative Pharmacology
Head-to-head clinical analysis: JUNEL FE 1 5 30 versus JUNEL FE 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNEL FE 1 5 30 versus JUNEL FE 1 20.
JUNEL FE 1.5/30 vs JUNEL FE 1/20
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus and endometrium to impede sperm penetration and implantation.
Prevention of pregnancyTreatment of moderate acne vulgaris (in females ≥15 years who desire contraception and have not responded to topical therapy)
Prevention of pregnancyTreatment of moderate acne vulgaris (in females at least 15 years of age who have no known contraindications to oral contraceptive therapy and have achieved menarche)Management of menstrual disorders (off-label)
One tablet orally once daily, each tablet containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets).
One tablet orally once daily for 21 days, followed by 7 days of placebo tablets. Each active tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol.
None Documented
None Documented
Norethindrone: 6-12 hours (terminal, multidose); ethinyl estradiol: 12-18 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; missed doses may reduce contraceptive efficacy.
Ethinyl estradiol: 13-27 hours (terminal); norethindrone: 5-14 hours (terminal). Clinically, steady-state is achieved within 5-6 days.
Ethinyl estradiol: primarily metabolized via CYP3A4; norethindrone: primarily reduced and conjugated, with CYP3A4 involvement.
Ethinyl estradiol is primarily metabolized by CYP3A4; norethindrone is metabolized by reduction and conjugation (glucuronidation and sulfation).
Renal: 30-50% (norethindrone metabolites), 20-40% (ethinyl estradiol metabolites); biliary/fecal: 20-30% (norethindrone), 30-50% (ethinyl estradiol). Conjugated metabolites excreted in bile and undergo enterohepatic recirculation.
Renal (primarily as metabolites; ~50-60% of dose), fecal (~30-40% of dose). Unchanged drug excretion is minimal.
Norethindrone: 60-80% bound to albumin and SHBG; ethinyl estradiol: ~98% bound to albumin (specific binding to SHBG not significant).
Ethinyl estradiol: ~97% bound to albumin; norethindrone: ~61% bound to albumin and sex hormone-binding globulin (SHBG).
Norethindrone: 2-4 L/kg; ethinyl estradiol: 5-10 L/kg. Clinical meaning: Indicates extensive tissue distribution and slow clearance; Vd may increase in obesity.
Ethinyl estradiol: 2.0-4.0 L/kg; norethindrone: 3.0-4.5 L/kg. Indicates extensive tissue distribution.
Oral: Norethindrone ~60-70% (first-pass metabolism); ethinyl estradiol ~40-50% (presystemic conjugation in gut and liver).
Oral: Ethinyl estradiol ~45% (due to first-pass metabolism); norethindrone ~64%.
No specific dose adjustment provided in labeling; use with caution in patients with renal impairment. GFR-based modifications not established.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min); use contraindicated in patients with renal disease or renal impairment if it worsens or is associated with hyperkalemia.
Contraindicated in patients with hepatic impairment (Child-Pugh class B or C) or active liver disease. No specific dose adjustment for mild impairment; use with caution.
Contraindicated in patients with hepatic impairment (Child-Pugh class A, B, or C) or active liver disease. No dose adjustment applicable.
Not indicated for use before menarche. In post-menarche adolescents, dosing is the same as adults: one tablet daily for 21 days, then 7 days placebo.
Safety and efficacy not established in pediatric patients. Not indicated for use before menarche.
Not indicated for use in postmenopausal women; no specific geriatric dosing considerations.
Not indicated for use in postmenopausal women. No specific geriatric dosing; contraindicated in women over 35 who smoke or have other risk factors.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women >35 years who smoke should not use this product.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives. This risk increases with age (especially in women over 35 years) and with heavy smoking (≥15 cigarettes per day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
["Increased risk of thromboembolic disorders (e.g., DVT, PE, stroke, MI)","Hepatic neoplasia risk","Liver disease (e.g., jaundice, hepatitis)","Elevated blood pressure","Gallbladder disease","Carbohydrate/lipid metabolic effects","Ocular lesions (e.g., retinal thrombosis)","Menstrual irregularities/breakthrough bleeding","Use in pregnancy (should be ruled out before initiation)","Depression"]
["Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction)","Hepatic neoplasia (benign and malignant)","Gallbladder disease","Hypertension","Carbohydrate and lipid metabolic effects","Headache","Bleeding irregularities","Depression","Ocular lesions (e.g., retinal thrombosis)","Carcinoma of the breast and reproductive organs","Use in pregnancy (discontinue if pregnancy occurs)"]
["Hypersensitivity to any component","Thrombophlebitis or thromboembolic disorders (current or history)","Cerebrovascular or coronary artery disease","Known or suspected pregnancy","Undiagnosed abnormal genital bleeding","Known or suspected breast cancer or other estrogen-sensitive neoplasia","Benign or malignant liver tumor (current or history)","Hepatic adenoma or carcinomas","Active liver disease with abnormal function tests","Major surgery with prolonged immobilization","Diabetes with vascular involvement","Uncontrolled hypertension","Migraine with focal neurological symptoms (current or history)","Smoking in women >35 years"]
["Thrombophlebitis, thromboembolic disorders, or history of these conditions","Cerebrovascular or coronary artery disease","Known or suspected breast cancer","Carcinoma of the endometrium or other estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior pill use","Hepatic adenoma or carcinoma","Known or suspected pregnancy","Hypersensitivity to any component","Use with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations"]
Data Pending Review
Data Pending Review
No specific food interactions are reported. However, grapefruit juice may increase ethinyl estradiol levels but interaction is considered weak; avoid excessive grapefruit juice consumption. Ferrous fumarate may reduce absorption of tetracycline antibiotics if taken together; space doses by at least 2 hours. No dietary restrictions are required.
No specific food restrictions. Grapefruit juice may theoretically increase estrogen levels but clinical significance is minimal; routine avoidance not required. Iron tablets (ferrous fumarate) may cause gastrointestinal upset; taking with food may reduce nausea. Avoid high-dose vitamin C supplements as they may increase estrogen absorption, but normal dietary intake is safe.
First trimester: Inadvertent use does not increase risk of major birth defects. Second and third trimesters: Avoid use due to risk of fetal harm from estrogenic and progestogenic effects, including potential genitourinary tract abnormalities. Postnatal effects: Possible long-term neurodevelopmental impacts reported in animal studies.
Pregnancy category X. Use is contraindicated during pregnancy due to risk of fetal harm. First trimester: Exposure is associated with cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal genital tract abnormalities (e.g., hypospadias, feminization of male fetuses).
Excreted in breast milk in small amounts; M/P ratio for ethinyl estradiol approximately 0.04–0.30. Progestin M/P ratio variable. May reduce milk production and quality. Use only if necessary and with caution, especially in early postpartum period.
Small amounts of ethinyl estradiol and norethindrone (the active components) are excreted into breast milk. The M/P ratio is approximately 0.1-0.3 for ethinyl estradiol and 0.5-1.0 for norethindrone. Use is generally not recommended during breastfeeding as it may reduce milk production and quality. If used, monitor infant for jaundice and growth.
Contraindicated during pregnancy; no dose adjustment exists. Discontinue immediately if pregnancy occurs. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are not applicable as drug is not used.
Contraindicated; no dose adjustment is indicated as the drug should be discontinued immediately upon pregnancy detection.
Category C
Category C
Junel Fe 1.5/30 is a combination oral contraceptive containing ethinyl estradiol 30 mcg and norethindrone 1.5 mg, with ferrous fumarate as placebo. Consider starting on first day of menses or first Sunday after onset. Missed pills increase pregnancy risk; if missing one pill, take as soon as remembered. For missed two pills in week 1 or 2, take two pills daily for two days and use backup contraception. If missed in week 3, consider finishing current pack and skipping placebo, or starting new pack the next day. Drug interactions include rifampin, certain anticonvulsants, and St. John's wort, which may reduce efficacy. Monitor for DVT, PE, stroke, and MI, especially in smokers over 35, hypertensive, diabetic, or obese patients.
Junel Fe 1/20 is a combined oral contraceptive (COC) containing ethinyl estradiol 20 mcg and norethindrone 1 mg. It is a low-dose pill; efficacy may be slightly lower than higher-dose pills. The iron supplement (ferrous fumarate) in the placebo pills is not intended for contraception; patients should not skip active pills. Missed pills increase risk of ovulation; if one active pill is missed, take it as soon as remembered and continue; if two or more are missed, use backup contraception for 7 days. Counsel on signs of venous thromboembolism (VTE): sudden leg pain, chest pain, shortness of breath. Consider alternatives in migraine with aura, uncontrolled hypertension, or smokers over 35. Drug interactions include rifampin, certain anticonvulsants (phenytoin, carbamazepine), and St. John's Wort which may reduce efficacy.
Take one tablet daily at the same time; do not skip days.If you miss a pill, refer to the package instructions or ask your healthcare provider.Use backup contraception (e.g., condoms) if you miss pills or start late.Common side effects include nausea, breast tenderness, and breakthrough bleeding.Seek emergency care for severe abdominal pain, chest pain, leg swelling, or vision changes.Smoking increases risk of serious cardiovascular effects; avoid smoking, especially if over 35.Iron supplements are included; ferrous fumarate in placebo tablets is not effective for contraception.
Take one pill daily at the same time; the last 7 pills in each pack are iron tablets and do not provide contraception.If you miss an active pill, take it as soon as you remember. If you miss two or more active pills, use a backup contraceptive method (e.g., condoms) for the next 7 days.Vomiting or severe diarrhea within 4 hours of taking an active pill may reduce effectiveness; treat as a missed pill and consult your clinician.Notify your clinician if you experience severe leg pain, chest pain, shortness of breath, severe headache, or vision changes.Avoid smoking while on this medication, especially if over 35 years old, as it increases the risk of serious cardiovascular events.Inform your clinician of all medications you take, including over-the-counter products and herbal supplements.